Managing Toxicities of Bispecific Antibodies in Multiple Myeloma–Drs. Hamza Hashmi & Cesar Rodriguez

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists.Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11oApple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Key topics included:Overview of bispecific antibodies, focusing on GPRC5D and BCMA-targeted therapies.Detailed discussion on talquetamab, teclistamab, elranatamab, and linvoseltamab, including dosing, side effects, and management strategies.Insights on managing cytokine release syndrome (CRS), neurotoxicity, and other side effects like dysgeusia, skin toxicity, and infections.Prophylactic measures, including the use of IVIG and tocilizumab, to enhance patient care and quality of life.Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!#MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers